This article was originally published in The Rose Sheet
Executive SummaryBlades and Razors sales advanced 11% to $1.21 bil. on a reported basis, and profit from operations in the unit increased 16% to $488 mil. in the second quarter, Gillette announces Aug. 4. Results were boosted in part by a double-digit sales increase in North America for the Venus women's shaving brand, which benefited from the launch of Venus Vibrance and new Venus Disposable razor. Gillette's global value share of the blades/razors segment increased by more than one percentage point to 71.5%, while M3Power remained the top-selling men's razor in North America and worldwide with a 19% value share, according to the firm. Personal care sales were up 9% to $256 mil., with profit from operations advancing 25% to $30 mil., reflecting improved product mix and "ongoing trade-up from shaving foams to gels," company notes. Net sales rose 13.4% to $2.77 bil., while net income increased 16.9% to $498 mil...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.